Evidence map›Paper›PMID 32224864›Full record

ArticleCancers2020

A Novel Role for the Tumor Suppressor Gene

Olga Pernía, Ana Sastre-Perona, Carlos Rodriguez-Antolín, Alvaro García-Guede, María Palomares-Bralo, Rocío Rosas, Darío Sanchez-Cabrero, Patricia Cruz, Carmen Rodriguez, MDolores Diestro and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Nutrients · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Olga PerníaEpigenetics Laboratory, INGEMM, Hospital La PAZ, 28046 Madrid, Spain.
Ana Sastre-PeronaEpigenetics Laboratory, INGEMM, Hospital La PAZ, 28046 Madrid, Spain.
Carlos Rodriguez-AntolínEpigenetics Laboratory, INGEMM, Hospital La PAZ, 28046 Madrid, Spain.
Alvaro García-GuedeEpigenetics Laboratory, INGEMM, Hospital La PAZ, 28046 Madrid, Spain.
María Palomares-BraloCiber de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
Rocío RosasEpigenetics Laboratory, INGEMM, Hospital La PAZ, 28046 Madrid, Spain.
Darío Sanchez-CabreroExperimental Therapies and Novel Biomarkers in Cancer IdiPAZ, 28046 Madrid, Spain.
Patricia CruzExperimental Therapies and Novel Biomarkers in Cancer IdiPAZ, 28046 Madrid, Spain.
Carmen RodriguezEpigenetics Laboratory, INGEMM, Hospital La PAZ, 28046 Madrid, Spain.
MDolores DiestroGynaecologic Oncology Unit, La Paz University Hospital, 28046 Madrid, Spain.
Rubén Martín-ArenasCiber de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
Verónica PulidoEpigenetics Laboratory, INGEMM, Hospital La PAZ, 28046 Madrid, Spain.ORCID 0000-0002-3127-8131
Pilar SantistebanInstituto de Investigaciones Biomedicas CSIC/UAM, 28029 Madrid, Spain.
Javier de CastroExperimental Therapies and Novel Biomarkers in Cancer IdiPAZ, 28046 Madrid, Spain.
Olga VeraDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Inmaculada Ibáñez de CáceresEpigenetics Laboratory, INGEMM, Hospital La PAZ, 28046 Madrid, Spain.ORCID 0000-0002-1878-4945
Hospital Universitario La Paz · ESInstituto de Salud Carlos III · ESLight Prescriptions Innovators (Spain) · ESMoffitt Cancer Center · US

Funding

TREATMENT UTILIZATION AND TREATMENT NEEDSR01DA003724 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI BRUNSWICK, ANN F · 1985 to 1986
–
Comunidad de Madrid B2017/BMD-3724European Regional Development Fund -Fundación Científica Asociación Española Contra el Cáncer GCB14142311CRESInstituto de Salud Carlos III CM19/00100Instituto de Salud Carlos III CP19/00063Instituto de Salud Carlos III PI15/00186Instituto de Salud Carlos III PI18/00050Ministerio de Economía, Industria y Competitividad, Gobierno de España RTC-2016-5314-1Ministerio de Economía, Industria y Competitividad, Gobierno de España SAF2016-75531-R
6 · The paper itself

Abstract

Despite often leading to platinum resistance, platinum-based chemotherapy continues to be the standard treatment for many epithelial tumors. In this study we analyzed and validated the cytogenetic alterations that arise after treatment in four lung and ovarian paired cisplatin-sensitive/resistant cell lines by 1-million microarray-based comparative genomic hybridization (array-CGH) and qRT-PCR methodologies. RNA-sequencing, functional transfection assays, and gene-pathway activity analysis were used to identify genes with a potential role in the development of this malignancy. The results were further explored in 55 lung and ovarian primary tumors and control samples, and in two extensive in silico databases. Long-term cell exposure to platinum induces the frequent deletion of

Indexed as

chemotherapy resistanceHOXD9ITF2-TCF4NSCLCWnt pathway

Identifiers

PMID32224864
PMCPMC7226299
OpenAlexW3009298674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.